Global Bioresorbable Vascular Scaffold Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The Global Bioresorbable Vascular Scaffold (BVS) Market is segmented by Product, Material, End User, and Geography, product into drug-eluting scaffolds and bare scaffolds. Drug-eluting bioresorbable vascular scaffolds are designed to release therapeutic agents over time, preventing restenosis (re-narrowing of the blood vessel) and promoting healing. These scaffolds are increasingly favored in coronary artery disease treatments due to their ability to combine mechanical support with the benefits of drug delivery. Bare bioresorbable scaffolds, which provide temporary mechanical support without drug release, are also used but face more competition from drug-eluting variants, as they primarily focus on providing scaffolding that dissolves over time, reducing the need for a second intervention.

In terms of material, the bioresorbable vascular scaffold market is segmented into polymers and metals. Polymer-based scaffolds, such as those made from PLLA (Poly L-lactide) and PLGA (Poly lactic-co-glycolic acid), dominate the market due to their favorable properties like biocompatibility, controlled degradation rates, and flexibility. These materials are well-suited for drug-eluting designs and offer improved patient outcomes by supporting vascular healing while avoiding long-term complications. Metal-based scaffolds, made primarily from magnesium alloys, are gaining attention for their strength and potential for longer-term support, but their degradation rate is a key area of ongoing research to ensure optimal performance.

The market is also segmented by end-user, with hospitals and clinics holding the largest share due to their role in cardiovascular procedures. These healthcare settings are where the majority of bioresorbable vascular scaffolds are used in treating patients with coronary artery disease, particularly in percutaneous coronary interventions (PCIs). The increasing prevalence of heart disease and the growing adoption of minimally invasive procedures further boost the demand for bioresorbable scaffolds. Geographically, North America and Europe lead the market due to advanced healthcare infrastructure, high adoption rates of innovative technologies, and strong regulatory support for bioresorbable devices. However, the Asia-Pacific region is experiencing rapid growth, driven by increasing healthcare investments, rising cardiovascular disease rates, and a growing demand for advanced medical technologies in countries like China and India.

Global Bioresorbable Vascular Scaffold Segment Analysis

In this report, the Global Bioresorbable Vascular Scaffold Market has been segmented by Product, Material, End User, and Geography.

Global Bioresorbable Vascular Scaffold Market, Segmentation by Product

The Global Bioresorbable Vascular Scaffold Market has been segmented by Product into Synthetic and Biological.

The Global Bioresorbable Vascular Scaffold Market is segmented by product into two main categories: synthetic and biological scaffolds. Synthetic bioresorbable vascular scaffolds are made from engineered materials, such as polymers and metals, that are designed to provide mechanical support to blood vessels while gradually degrading over time. These scaffolds are widely used in coronary artery disease treatments due to their predictable degradation rates and ability to provide temporary support during the healing process. Synthetic materials, including PLLA (Poly L-lactide) and PLGA (Poly lactic-co-glycolic acid), offer customizable mechanical properties and biocompatibility, making them a popular choice for drug-eluting scaffolds that can prevent restenosis and support long-term vascular healing.

On the other hand, biological bioresorbable vascular scaffolds are derived from natural sources such as collagen, elastin, or other biologically sourced materials. These scaffolds are designed to mimic the natural extracellular matrix of blood vessels, promoting better integration with the surrounding tissue and enhancing healing. Biological scaffolds offer advantages in terms of biocompatibility and the potential for reducing the risk of inflammation and immune responses. However, they are often less durable than synthetic scaffolds and are still in the development stage for broader clinical applications. Their ability to naturally integrate and degrade within the body makes them a promising option for patients requiring minimal long-term mechanical support.

Both synthetic and biological bioresorbable vascular scaffolds are evolving to meet the growing demand for minimally invasive cardiovascular treatments. While synthetic scaffolds currently dominate the market due to their proven effectiveness and ease of manufacturing, biological scaffolds are gaining attention for their potential in enhancing tissue regeneration and reducing long-term complications. As research progresses, the market is likely to see a greater convergence between these two types of scaffolds, with hybrid solutions combining the advantages of both synthetic and biological materials to optimize patient outcomes. This segmentation reflects the diverse needs within the vascular healthcare sector, where personalized and effective solutions are becoming increasingly important.

Global Bioresorbable Vascular Scaffold Market, Segmentation by Material

The Global Bioresorbable Vascular Scaffold Market has been segmented by Material into Coronary Artery Stents, Peripheral Artery Stent, and Others.

Coronary artery stents represent one of the primary categories within the material segmentation of the BVS market. These stents are specifically designed for use in the coronary arteries, which supply oxygen-rich blood to the heart muscle. Coronary artery stents play a critical role in the treatment of coronary artery disease (CAD) by providing mechanical support to diseased or narrowed coronary arteries, thereby improving blood flow and relieving symptoms such as angina. Bioresorbable vascular scaffolds used in coronary artery stenting offer temporary structural support to the vessel wall while gradually degrading over time, allowing for vascular healing and restoration of physiological function.

Peripheral artery stents constitute another important category within the material segmentation of the BVS market. Unlike coronary artery stents, which are deployed in the coronary arteries, peripheral artery stents are used to treat blockages or narrowing in the peripheral arteries located outside the heart, such as those in the legs, arms, abdomen, or pelvis. Peripheral artery disease (PAD) can lead to symptoms such as leg pain, cramping, and impaired mobility, necessitating intervention with vascular stents to restore blood flow and alleviate symptoms. Bioresorbable vascular scaffolds designed for peripheral artery stenting offer similar benefits as their coronary counterparts, providing temporary support to the vessel while allowing for gradual resorption and vascular healing.

The material segmentation of the BVS market encompasses other specialized devices used in specific vascular applications or anatomical locations. These may include bioresorbable scaffolds designed for use in carotid arteries, renal arteries, iliac arteries, or other vascular territories affected by atherosclerosis or other vascular conditions. The development of specialized bioresorbable scaffolds tailored to unique anatomical challenges and clinical indications underscores the versatility and potential of this innovative technology in addressing a broad spectrum of vascular diseases and patient needs.

Global Bioresorbable Vascular Scaffold Market, Segmentation by End User

The Global Bioresorbable Vascular Scaffold Market has been segmented by End User into Hospitals, Ambulatory Surgical Centers, Cardiac Center, and Others.

Hospitals represent one of the primary end user categories within the segmentation of the BVS market. Hospitals serve as the focal point for advanced cardiovascular care, offering a wide range of diagnostic, therapeutic, and surgical services to patients with cardiovascular diseases. Within hospital settings, bioresorbable vascular scaffolds are utilized in cardiac catheterization laboratories (cath labs) during percutaneous coronary interventions (PCIs), where interventional cardiologists implant scaffolds to treat coronary artery disease and restore blood flow to the heart muscle. Hospitals with specialized cardiac units or comprehensive heart centers may have dedicated facilities and personnel for managing complex cardiovascular cases and performing advanced interventions using bioresorbable vascular scaffolds.

Ambulatory surgical centers (ASCs) represent another important end user category within the segmentation of the BVS market. ASCs are outpatient facilities that specialize in providing same-day surgical and interventional procedures in a more convenient and cost-effective setting compared to traditional hospital environments. Bioresorbable vascular scaffolds may be deployed in ASCs for selected patients undergoing elective coronary interventions or peripheral artery procedures, offering the benefits of shorter recovery times, reduced hospitalization costs, and increased patient satisfaction. ASCs equipped with state-of-the-art cath lab facilities and experienced interventionalists can provide high-quality care for patients requiring bioresorbable vascular scaffold implantation.

Cardiac centers, including specialized heart hospitals, cardiovascular institutes, and cardiac care units within larger healthcare facilities, represent a distinct end user category within the segmentation of the BVS market. These centers focus on the diagnosis, treatment, and management of various cardiovascular conditions, offering comprehensive services ranging from non-invasive diagnostics to complex interventional procedures. Bioresorbable vascular scaffolds play a pivotal role in the treatment of coronary artery disease within cardiac centers, where multidisciplinary teams of cardiologists, cardiac surgeons, and support staff collaborate to deliver optimal care to patients with complex cardiac conditions.

The end user segmentation of the BVS market includes other healthcare facilities where bioresorbable vascular scaffolds may be utilized, such as specialty clinics, academic medical centers, and research institutions. These facilities may participate in clinical trials, research studies, or specialized treatment programs involving bioresorbable vascular scaffolds, contributing to the advancement of scientific knowledge and clinical practice in the field of interventional cardiology and vascular medicine.

Global Bioresorbable Vascular Scaffold Market, Segmentation by Geography

In this report, the Global Bioresorbable Vascular Scaffold Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Bioresorbable Vascular Scaffold Market Share (%), by Geographical Region, 2024

North America stands as a prominent market segment within the BVS market geography. With advanced healthcare systems, robust research and development infrastructure, and high prevalence of cardiovascular diseases, North America represents a key region for the adoption of bioresorbable vascular scaffolds. The United States and Canada are major contributors to market growth, driven by factors such as technological advancements, reimbursement policies, and clinical expertise in interventional cardiology.

Europe is another significant market segment within the geography of the BVS market. European countries boast well-established healthcare systems, renowned medical institutions, and a strong tradition of clinical research and innovation. Countries such as Germany, France, and the United Kingdom are key players in the European BVS market, with active participation in clinical trials, regulatory approvals, and adoption of bioresorbable vascular scaffold technology in cardiovascular care.

The Asia Pacific region represents a rapidly growing market segment for bioresorbable vascular scaffolds, fueled by increasing healthcare investments, rising prevalence of cardiovascular diseases, and expanding access to advanced medical technologies. Countries such as China, Japan, and India are driving market growth in the Asia Pacific region, with growing demand for minimally invasive cardiovascular interventions and a shift towards value-based healthcare delivery models.

The Middle East and Africa (MEA) region presents unique opportunities and challenges within the geography of the BVS market. While the region experiences a high burden of cardiovascular diseases, access to advanced medical technologies and specialized cardiovascular care may vary across different countries. Emerging economies in the Middle East and Africa, such as the United Arab Emirates, Saudi Arabia, and South Africa, are investing in healthcare infrastructure and expanding cardiovascular services, creating opportunities for the adoption of bioresorbable vascular scaffold technology.

Latin America represents another important market segment within the BVS market geography. Countries in Latin America, including Brazil, Mexico, and Argentina, are witnessing increasing demand for cardiovascular interventions and growing awareness of advanced treatment options such as bioresorbable vascular scaffolds. Regulatory harmonization efforts, investment in healthcare infrastructure, and collaborations with international stakeholders are driving market growth in the Latin American region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Bioresorbable Vascular Scaffold Market. These factors include; Market Drivers, Restraints, and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Increasing cardiovascular disease prevalence
• Demand for minimally invasive interventions
• Adoption of value-based healthcare models
• Aging population

• Focus on reducing long-term complications - The drive to mitigate long-term complications serves as a significant driver in the bioresorbable vascular scaffold (BVS) market, propelling advancements aimed at enhancing patient outcomes and safety over time. Recognizing the importance of reducing complications associated with cardiovascular interventions, healthcare providers and manufacturers are intensifying efforts to develop bioresorbable scaffolds that address long-term concerns, such as thrombosis and restenosis, often associated with permanent metallic stents.

  This driver underscores a fundamental shift towards improving the long-term durability and effectiveness of vascular interventions, particularly in coronary artery disease management. Bioresorbable vascular scaffolds offer a promising solution by providing temporary support to diseased arteries while gradually dissolving, allowing the vessel to regain its natural function. By eliminating the presence of a permanent foreign body within the artery, bioresorbable scaffolds have the potential to minimize the risk of late complications, including stent thrombosis and in-stent restenosis, which can adversely impact patient outcomes and quality of life.

  The focus on reducing long-term complications reflects a broader commitment to optimizing patient care and enhancing treatment efficacy in interventional cardiology. Healthcare providers are increasingly prioritizing interventions that not only alleviate symptoms and restore blood flow but also promote sustained vascular healing and minimize adverse events over the patient's lifetime. Bioresorbable vascular scaffolds represent a promising technological advancement in this regard, offering a temporary scaffold that gradually disappears, allowing the vessel to remodel and potentially reducing the risk of late complications compared to permanent metallic stents.

Restraints

• Operator variability
• Scaffold degradation challenges
• Regulatory hurdles and approval delays
• Uncertainty in patient selection criteria

• Device thrombosis concerns - Device thrombosis concerns represent a significant restraint in the adoption and utilization of bioresorbable vascular scaffolds (BVS) in cardiovascular interventions. Thrombosis, or the formation of blood clots within the scaffold, poses a serious complication that can lead to adverse clinical outcomes, including myocardial infarction and death. The risk of device thrombosis is particularly concerning in the context of bioresorbable scaffolds, where the scaffold's gradual resorption may alter the vessel environment and affect platelet adhesion and clotting mechanisms.

  This restraint is compounded by the limited long-term clinical data available on bioresorbable scaffold safety and efficacy, which contributes to uncertainty among clinicians regarding the optimal management of patients treated with these devices. While bioresorbable scaffolds offer the potential for vascular healing and restoration of physiological function, concerns about thrombosis risk have led to cautious adoption and selective use of these devices in clinical practice.

  The incidence of device thrombosis remains a subject of ongoing research and debate, with studies reporting variable rates depending on patient characteristics, procedural factors, and scaffold design. Factors such as inadequate dual antiplatelet therapy, incomplete scaffold apposition, and suboptimal scaffold deployment techniques have been implicated in thrombotic events, highlighting the importance of meticulous procedural planning and post-procedural monitoring to minimize thrombosis risk.

Opportunities

• Diversification of scaffold applications
• Streamlining approval processes
• Advanced imaging integration
• Patient-centered care models

• Physician training initiatives - Physician training initiatives present a valuable opportunity to address the challenges and optimize the utilization of bioresorbable vascular scaffolds (BVS) in cardiovascular interventions. As the adoption of BVS technology continues to evolve, there is a growing recognition of the importance of comprehensive physician training programs to ensure procedural competence, enhance patient safety, and maximize clinical outcomes.

  Physician training initiatives offer a structured approach to educating interventional cardiologists and other healthcare professionals on the principles of bioresorbable scaffold technology, procedural techniques, and patient selection criteria. By providing hands-on training opportunities, didactic lectures, and case-based discussions, these initiatives equip clinicians with the knowledge and skills necessary to effectively integrate BVS into their clinical practice.

  Physician training programs play a crucial role in promoting standardized procedural protocols and best practices for bioresorbable scaffold implantation, thereby reducing procedural variability and minimizing the risk of complications. Training initiatives emphasize the importance of meticulous lesion assessment, optimal scaffold sizing, precise deployment techniques, and post-procedural monitoring to ensure successful outcomes and mitigate adverse events.

Key players in Global Bioresorbable Vascular Scaffold Market include,

• Abbott
• Medtronic
• Boston Scientific Corporation
• Biotronik
• Elixir Medical Corporation
• REVA Medical
• Amaranth Medical
• Kyoto Medical Planning
• Xenogenics Corporation
• B. Braun
• Cardinal Health
• Lombard Medical
• Translumina
• MicroPort Scientific Corporation
• TERUMO CORPORATION

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis